Citius Oncology Inc. (CTOR) Forward Price-to-Revenue Multiple
Citius Oncology, Inc. (CTOR) attracts leading oncologists through generous options to commercialize therapies, reinforcing the brand's status as a valuable niche expert. The projected market capitalization-to-revenue ratio demonstrates valuation dynamics where the 8.60 mark serves as a current indicator. The company is developing an immunotherapy-based cancer combat system by integrating Lymphir into treatment protocols for rare lymphomas.
Analytical breakdowns for Citius Oncology, Inc.
- current price and projected stock value:
- market capitalization details:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Citius Oncology, Inc.|CTOR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Citius Oncology|CTOR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Citius Oncology Inc|CTOR - Long-Term Debt|Company Short-Term Debt Citius Oncology|Quick Ratio citiusonc.com
- financial results and valuation multiples details:
CTOR - Net Income|Expected Profit Citius Oncology, Inc.|CTOR - Market Cap to Earnings|Future Price to Earnings Citius Oncology, Inc.|CTOR - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology Inc|CTOR - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Citius Oncology|CTOR - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months citiusonc.com|CTOR - Earnings per share growth rate in current year|Expected earnings per share growth for next year Citius Oncology, Inc.
- sales volume and revenue indicators:
Summary company analysis:CTOR (citiusonc.com)
Citius Oncology, Inc. (CTOR) maintains a stable workforce and retains leading biochemists, creating a foundation for future sales that directly impacts market expectations. By analyzing the company's forward P/S on GURU.Markets, an investor can view the ratio of market capitalization to expected revenue, allowing for an assessment of the asset's premium and the timely balancing of risks through the price action reflected in this chart.
Competitor analysis
Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple
